Cargando…
Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontli...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480919/ https://www.ncbi.nlm.nih.gov/pubmed/22913602 http://dx.doi.org/10.1186/1475-2867-12-38 |